File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study

TitleWaning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study
Authors
KeywordsBNT162b2
CoronaVac
COVID-19
Omicron
waning vaccine effectiveness
Issue Date18-May-2023
PublisherTaylor and Francis Group
Citation
Emerging Microbes & Infections, 2023, v. 12, n. 1 How to Cite?
Abstract

Background: This study aims to evaluate waning effectiveness against severe and fatal COVID-19 with two to three doses of CoronaVac/BNT162b2, where data are limited. Methods: A case–control study included individuals aged ≥18 years, unvaccinated or received two to three doses of CoronaVac/BNT162b2, using electronic healthcare databases in Hong Kong. Those with first COVID-19-related hospitalization, severe complications, or mortality between 1 January and 15 August 2022 were defined as cases and matched with up-to-10 controls by age, sex, index date, and Charlson Comorbidity Index. Vaccine effectiveness (VE) against COVID-19-related outcomes was estimated at different time intervals from second and third-dose vaccination (0–13 up-to 210–240 days) using conditional logistic regression adjusted for comorbidities and medications. Results: By 211–240 days after second dose, VE against COVID-19-related hospitalization reduced to 46.6% (40.7–51.8%) for BNT162b2 and 36.2% (28.0–43.4%) for CoronaVac, and VE against COVID-19-related mortality were 73.8% (55.9–84.4%) and 76.6% (60.8–86.0%). After third dose, VE against COVID-19-related hospitalization decreased from 91.2% (89.5–92.6%) for BNT162b2 and 76.7% (73.7–79.4%) for CoronaVac at 0–13 days, to 67.1% (60.4–72.6%) and 51.3% (44.2–57.5%) at 91–120 days. VE against COVID-19-related mortality for BNT162b2 remained high from 0–13 days [98.2% (95.0–99.3%)] to 91–120 days [94.6% (77.7–98.7%)], and for CoronaVac reduced from 0–13 days [96.7% (93.2–98.4%)] to 91–120 days [86.4% (73.3–93.1%)]. Conclusions: Significant risk reduction against COVID-19-related hospitalization and mortality after CoronaVac or BNT162b2 vaccination was observed for >240 and >120 days after second and third doses compared to unvaccinated, despite significant waning over time. Timely administration of booster doses could provide higher levels of protection.


Persistent Identifierhttp://hdl.handle.net/10722/336560
ISSN
2021 Impact Factor: 19.568
2020 SCImago Journal Rankings: 2.475

 

DC FieldValueLanguage
dc.contributor.authorYan, Vincent Ka Chun-
dc.contributor.authorWan, Eric Yuk Fai-
dc.contributor.authorYe, Xuxiao-
dc.contributor.authorMok, Anna Hoi Ying-
dc.contributor.authorLai, Francisco Tsz Tsun-
dc.contributor.authorChui, Celine Sze Ling-
dc.contributor.authorLi, Xue-
dc.contributor.authorWong, Carlos King Ho-
dc.contributor.authorLi, Philip Hei-
dc.contributor.authorMa, Tiantian-
dc.contributor.authorQin, Simon-
dc.contributor.authorLau, Chak Sing-
dc.contributor.authorWong, Ian Chi Kei-
dc.contributor.authorChan, Esther Wai Yin-
dc.date.accessioned2024-02-16T10:31:40Z-
dc.date.available2024-02-16T10:31:40Z-
dc.date.issued2023-05-18-
dc.identifier.citationEmerging Microbes & Infections, 2023, v. 12, n. 1-
dc.identifier.issn2222-1751-
dc.identifier.urihttp://hdl.handle.net/10722/336560-
dc.description.abstract<p>Background: This study aims to evaluate waning effectiveness against severe and fatal COVID-19 with two to three doses of CoronaVac/BNT162b2, where data are limited. Methods: A case–control study included individuals aged ≥18 years, unvaccinated or received two to three doses of CoronaVac/BNT162b2, using electronic healthcare databases in Hong Kong. Those with first COVID-19-related hospitalization, severe complications, or mortality between 1 January and 15 August 2022 were defined as cases and matched with up-to-10 controls by age, sex, index date, and Charlson Comorbidity Index. Vaccine effectiveness (VE) against COVID-19-related outcomes was estimated at different time intervals from second and third-dose vaccination (0–13 up-to 210–240 days) using conditional logistic regression adjusted for comorbidities and medications. Results: By 211–240 days after second dose, VE against COVID-19-related hospitalization reduced to 46.6% (40.7–51.8%) for BNT162b2 and 36.2% (28.0–43.4%) for CoronaVac, and VE against COVID-19-related mortality were 73.8% (55.9–84.4%) and 76.6% (60.8–86.0%). After third dose, VE against COVID-19-related hospitalization decreased from 91.2% (89.5–92.6%) for BNT162b2 and 76.7% (73.7–79.4%) for CoronaVac at 0–13 days, to 67.1% (60.4–72.6%) and 51.3% (44.2–57.5%) at 91–120 days. VE against COVID-19-related mortality for BNT162b2 remained high from 0–13 days [98.2% (95.0–99.3%)] to 91–120 days [94.6% (77.7–98.7%)], and for CoronaVac reduced from 0–13 days [96.7% (93.2–98.4%)] to 91–120 days [86.4% (73.3–93.1%)]. Conclusions: Significant risk reduction against COVID-19-related hospitalization and mortality after CoronaVac or BNT162b2 vaccination was observed for >240 and >120 days after second and third doses compared to unvaccinated, despite significant waning over time. Timely administration of booster doses could provide higher levels of protection.</p>-
dc.languageeng-
dc.publisherTaylor and Francis Group-
dc.relation.ispartofEmerging Microbes & Infections-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBNT162b2-
dc.subjectCoronaVac-
dc.subjectCOVID-19-
dc.subjectOmicron-
dc.subjectwaning vaccine effectiveness-
dc.titleWaning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study-
dc.typeArticle-
dc.identifier.doi10.1080/22221751.2023.2209201-
dc.identifier.scopuseid_2-s2.0-85159759999-
dc.identifier.volume12-
dc.identifier.issue1-
dc.identifier.eissn2222-1751-
dc.identifier.issnl2222-1751-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats